Document Detail

Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.
MedLine Citation:
PMID:  14614357     Owner:  NLM     Status:  MEDLINE    
We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode. The patient had none of the risk factors known to influence the response to the coumarinic derivative except that she carried the rare *3 allelic variant of the cytochrome P450 CYP2C9 in a homozygous status. This case illustrates the role of the *3 polymorphism of the cytochrome P450 CYP2C9 as an independent risk factor modulating the sensitivity of patients to the anticoagulant effect of acenocoumarol. The usefulness of CYP2C9 genotyping before starting coumarinic treatments is discussed.
Elisabeth André-Kerneïs; Catherine Leroy-Matheron; Michèle Gouault-Heilmann
Related Documents :
22730847 - Reports to the navy's family advocacy program: impact of removal of mandatory reporting...
8110927 - Thrombotic microangiopathy associated with streptococcus pneumoniae bacteremia: case re...
11954887 - Thrombotic thrombocytopenic purpura as an initial presentation of primary sjögren's sy...
15009067 - Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and ...
20201637 - Cardiac tamponade after malignant superior vena cava stenting: two case reports and bri...
8218677 - Cerebrospinal fluid rhinorrhea and recurrent meningitis.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis     Volume:  14     ISSN:  0957-5235     ISO Abbreviation:  Blood Coagul. Fibrinolysis     Publication Date:  2003 Dec 
Date Detail:
Created Date:  2003-11-17     Completed Date:  2004-12-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9102551     Medline TA:  Blood Coagul Fibrinolysis     Country:  England    
Other Details:
Languages:  eng     Pagination:  761-4     Citation Subset:  IM    
Unité d'Hémostase de Thrombose, Service d'Hématologie Biologique, Centre Hospitalier Universitaire Henri Mondor, Créteil, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acenocoumarol / adverse effects*,  therapeutic use
Anticoagulants / adverse effects*,  therapeutic use
Aryl Hydrocarbon Hydroxylases / genetics*
Blood Coagulation Disorders / chemically induced*,  enzymology,  genetics
Polymorphism, Genetic*
Risk Factors
Thrombosis / drug therapy
Reg. No./Substance:
0/Anticoagulants; 152-72-7/Acenocoumarol; EC Hydrocarbon Hydroxylases; EC protein, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Specific elevation in plasma tissue plasminogen activator antigen concentrations in South Asians rel...
Next Document:  Eczematous plaques related to unfractionated and low-molecular-weight heparin in pregnancy: cross-re...